Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01969370 · ClinicalTrials.gov registry record · NA

NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing

A NA study of Cancer and Cardiovascular Disease, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
NA
Development phase
645
Enrollment target
1
Study location

NCT01969370 is a NA study of Cancer and Cardiovascular Disease that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 645 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01969370, a NA study of Cancer and Cardiovascular Disease, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
NA
Development phase
645 participants
Enrollment target
1
Study location

Study Summary

This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. This sub-project is investigating benefits and harms of providing WES diagnostic and different types of incidental findings to adult patients and parents of pediatric patients who undergo WES because they have symptoms suggesting genetic disease.

Interventions

  • BEHAVIORAL Experimental

Study Locations (1)

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 645 participants
Start Date 2012-08
Est. Completion 2017-03-01
Phase NA

What the Registry Record Tells You About NCT01969370

The ClinicalTrials.gov registry entry for NCT01969370 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 645 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (82% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Experimental is the first listed.

NCT01969370 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT01969370 about?

NCT01969370 is a clinical study titled "NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing". This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. This sub-project is investigating benefits and harms of providing WES diagnostic and different types of incidental...

What is the current status of trial NCT01969370?

This trial is currently completed. It is a NA study. The enrollment target is 645 participants. The study started on 2012-08. Estimated completion is 2017-03-01.

What conditions does trial NCT01969370 study?

This clinical trial studies the following conditions: Cancer, Cardiovascular Disease, Hearing Loss, Congenital Abnormalities, Neurologic Dysfunction.

What interventions are being tested in trial NCT01969370?

The interventions under investigation include: Experimental (BEHAVIORAL).

Who is sponsoring clinical trial NCT01969370?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01969370 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.